ClinicalTrials.gg
RecruitingNCT06697301Updated Oct 6, 2026

Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.

A Phase 2/3 interventional study of EIK1001 and Pembrolizumab (KEYTRUDA® ) in Advanced Melanoma, sponsored by Eikon Therapeutics. Recruiting at 127 sites in 24 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by Eikon Therapeutics · Phase 2/3, Interventional, and Treatment

From the registry’s dates

  • Started May 2025; still recruiting 1 year 5 months later.
Updated Oct 6, 2026Site recruiting status changedStudy contact changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
740
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 414 studies in Neoplasm Metastasis with a site in Spain — 78 open to participants now, 143 under way, 43 of them phase 3. Neoplasm Metastasis · Spain.

Planned enrollment
34th of 392
740 · median 165
Started
2025
with 27 others
Phase 2/3
12 of 414
3 open now
Primary completion
2035-12
later than 141 of 142 live
Registered
375th of 414
by date

Among the 414 studies in Neoplasm Metastasis with a site in Spain, this one is the 34th largest by planned enrollment of the 392 interventional ones that give a count, is one of 28 that started in 2025, is one of 12 in phase 2/3, reaches primary completion later than 141 of the 142 other live ones, and was the 375th registered.

Neoplasm Metastasis

4,046 studies on the registry are indexed under Neoplasm Metastasis; 888 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

78 of the 414 studies in Neoplasm Metastasis with a site in Spain are open now. Recruiting first, the newest first:

73 more — sign in →

All 78 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 689 Neoplasm Metastasis studies recruiting now, 536 (78%) set no upper age limit and 97 (14%) stop at 75 or younger; 48 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 414 studies in Neoplasm Metastasis with a site in Spain, or all of them as a file.
02

Study summary

The study is for patients with advanced melanoma who are eligible for standard therapy with Pembrolizumab.

Read the detailed description

This is a Multicenter, Randomized, Double-Blind, Active Comparator-Controlled, Adaptive Phase 2/3 Study to Evaluate the Safety and Efficacy of EIK1001 and Pembrolizumab Versus Placebo and Pembrolizumab as First-Line Therapy in Participants with Advanced Melanoma. The study includes dose optimization and expansion parts.

03

Conditions studied

  • Advanced Melanoma

Browse trials for

Keywords

  • Metastatic
  • Advanced
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

To be eligible for inclusion in this study, participants must:

  • Be ≥ 18 years of age on the day of signing of .
  • Have a of at least 3 months.
  • Have or cytologically confirmed Stage 3 (unresectable) or Stage 4 melanoma per AJCC 8th ed. and be eligible for standard therapy with pembrolizumab.
  • Have at least 1 lesion with at Baseline by CT or MRI according to (RECIST) 1.1 by assessment of local site Investigator/radiologist.
  • Have known BRAF V600 mutation status or consent to BRAF V600 mutation testing per local institutional standards during the screening period
  • Have completed prior radiotherapy at least 2 weeks prior to study treatment administration.
  • Have an Performance Status of 0 to 1.
  • Have adequate organ and marrow function as defined by normal CBC, coagulation, serum chemistry and liver function tests on specimens collected within 10 days of treatment start.
  • Have a negative serum pregnancy test within 72 hours prior to receiving the first dose of study medication (applies to women of [WOCBP]).
  • Be willing to use either 2 adequate methods of , 1 adequate method plus a hormonal method of contraception, or be willing to abstain from heterosexual activity throughout the study (Visit 1 to 120 days after the last dose of study therapy; applies to WOCBP who are not menopausal for > 2 years, post-hysterectomy/oophorectomy, or surgically sterilized).
  • Agree to use an approved adequate contraceptive method throughout the study (Visit 1 to 120 days after the last dose of study therapy; applies to sexually active male participants with a partner who is WOCBP).
  • Be willing and able to provide written, informed consent for the study.

Exclusion criteria

Exclusion Criteria:

A participant is excluded from the study if any of the following criteria apply:

  • Has melanoma of ocular origin.
  • Is currently enrolled in or has recently participated in a study of an IMP and received an IMP within 4 weeks or 5 half-lives (whichever is shorter) of administration of EIK1001 or placebo.
  • Prior to the 1St dose of EIK1001 or placebo, the prospective participant has received systemic therapy for advanced melanoma.
  • Note: prior or neoadjuvant melanoma therapies (such as or anti CTLA 4 therapies or BRAF/MEK inhibitors) are permitted if all related AEs have either returned to Baseline or stabilized, with a minimum of 6 months between the last dose of prior therapy and documented disease progression.
  • Experienced a ≥ Grade 3 AE while receiving prior anti PD 1 therapy.
  • Has had major surgery (\< 3 weeks prior to the first dose).
  • Has received a live-virus vaccination within 30 days of the first dose of study treatment.
  • Has a known history of prior , unless the participant has undergone potentially curative therapy with no evidence of disease recurrence for 5 years.
  • Has known active and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate if they are clinically stable for at least 4 weeks with no evidence of new or enlarging brain metastases. There must be no need for doses of for at least 2 weeks prior to study treatment administration.
  • There is a mean resting > 470 ms on triplicate .
  • There is active disease that has required systemic treatment in the past 2 years. The following autoimmune conditions are permitted: Type 1 diabetes, hypothyroidism (on hormone replacement), or- vitiligo, psoriasis and alopecia as long as no systemic treatment is required.
  • There is either chronic treatment with systemic steroids, other immunosuppressive medication, or either of these has been administered within 14 days of start of study treatment.
  • Note: Participants with asthma that require intermittent use of bronchodilators, inhaled steroids, or local steroid injections are eligible. Steroid replacement for adrenal insufficiency is also permitted.
  • There is a history of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/ interstitial lung disease.
  • There are any active infections requiring therapy.
  • There is uncontrolled (HIV) infection. HIV-infected participants with well-controlled HIV may enroll.
  • There is a positive test result for virus (HBV) or indicating presence of virus (it is expected that all participants will have been serologically tested for hepatitis B in advance of this study, with HBsAG, anti-HBc IgG, and anti-HBs as per ASCO 2020 Provisional Clinical Opinion [PCO] on universal Serologic testing for hepatitis B at the onset of anticancer therapy; screening should also include an anti-HCV test prior to start of cancer treatment:
  • There is a history or clinical evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study or interfere with the participant's participation for the full duration of the study
  • Known psychiatric or substance abuse disorder that would interfere with cooperation with study requirements.
  • There is a known history of regular illicit drug use and/or recent history (within the last year) of substance abuse (including alcohol).
  • Participant is pregnant, breastfeeding, or planning to conceive or father children within the projected duration of the study.
  • Participant is currently receiving medications known to be strong inhibitors or inducers of and CYP1A2.
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
740 participants (estimated)

Study arms

  • Active comparator
    Arm 1

    Participants in this arm will receive Placebo and Standard of Care (Pembrolizumab).

    Drug: Pembrolizumab (KEYTRUDA® )

  • Experimental
    Arm 2

    Participants in this arm will receive EIK1001 (selected dose 1) + Standard of Care (Pembrolizumab).

    Drug: EIK1001 · Drug: Pembrolizumab (KEYTRUDA® )

  • Experimental
    Arm 3

    Participants in this arm will receive EIK1001 (selected dose 2) + Standard of Care (Pembrolizumab).

    Drug: EIK1001 · Drug: Pembrolizumab (KEYTRUDA® )

Interventions

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS)

    Progression-free survival (PFS) is defined as the time from the date of randomization to documented progressive disease per RECIST 1.1 by BICR or death due to any cause, whichever occurs first.

    Time frame: up to 5 years

  2. Overall survival (OS)

    Overall survival (OS) defined as the time from randomization to death due to any cause.

    Time frame: up to 5 years

  3. Objective Response (OR) (Dose Optimization Only)

    Objective Response (OR; defined as participants who demonstrate confirmed complete response \[CR\] or partial response \[PR\] by Response Evaluation Criteria in Solid Tumors \[RECIST\] version 1.1 as assessed by the Investigator) (Dose Optimization Only).

    Time frame: up to 5 years

  4. Adverse Events (AEs) (Dose Optimization Only)

    Adverse events (AEs), and discontinuation of study treatment due to an AE (Dose Optimization Only). An AE is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment.

    Time frame: up to 2.5 years

Secondary outcomes

  1. Adverse Events (AEs) and Discontinuation of study treatment due to any AE.

    Adverse events (AEs), and discontinuation of study treatment due to any AE. An AE is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment.

    Time frame: up to 2.5 years

  2. Objective Response (OR)

    Objective response (OR) is defined as the participants who demonstrate confirmed response (CR) or partial response (PR) according to RECIST 1.1 by BICR.

    Time frame: up to 5 years

  3. Duration of Response (DOR).

    Duration of Response (DOR) is defined as the time from the first documented evidence of complete response (CR) or partial response (PR) until disease progression or death due to any cause, whichever occurs first according to RECIST 1.1 by BICR.

    Time frame: up to 5 years

  4. Progression Free Survival (PFS)

    Progression Free Survival (PFS) according to RECIST 1.1 by Investigator.

    Time frame: up to 5 years

  5. Objective Response (OR)

    Objective Response (OR) according to RECIST 1.1 by Investigator.

    Time frame: up to 5 years

  6. Duration of Response (DOR)

    Duration of Response (DOR) according to RECIST 1.1 by Investigator

    Time frame: up to 5 years

  7. Duration of Response (DOR) (Dose Optimization Only).

    Duration of Response (DOR) per RECIST 1.1 by Investigator (Dose Optimization Only).

    Time frame: up to 5 years

  8. Progression-free survival (PFS) per RECIST 1.1 by Investigator (Dose Optimization Only).

    Progression-free survival (PFS) per RECIST 1.1 by Investigator (Dose Optimization Only).

    Time frame: up to 5 years

  9. Overall survival (OS) (Dose Optimization Only)

    Overall survival (OS) defined as the time from randomization to death due to any cause (Dose Optimization Only).

    Time frame: up to 5 years

07

Study locations

125 of 127 sites recruiting

Showing the first 100 of 127 sites across 24 countries. Choose a country and city above to see the rest.

08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Dec 2035, 127 months after the start.

Of 27 phase 2/3 interventional studies under Neoplasm Metastasis, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 43 and three quarters within 98. This study's planned 127 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 18, 2024
First posted
Nov 20, 2024
StartActual
May 22, 2025
Primary completionEst.
Dec 2035
CompletionEst.
Dec 2040
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
26 sites added, 6 sites removed. 2 sites changed recruiting status (2 now suspended)
Show 2 sites
  • Aarhus Universitetshospital · Aarhus, DenmarkRecruiting→Suspended
  • Aalborg University Hospital · Aalborg, DenmarkRecruiting→Suspended
Show 26 added (8 Italy, 5 Germany, 5 Spain, 3 United States, 2 South Korea, 1 France, 1 Poland, 1 South Africa)
  • Christiana Care · Newark, United States
  • Florida Clinical Trials Group - Tamarac · Tamarac, United States
  • Patientcare Clinical Research · Sugar Land, United States
  • CHU Lille · Lille, France
  • University Hospital Erlangen · Erlangen, Germany
  • Universität Leipzig · Haus, Germany
  • University Hospital Carl Gustav Carus Dresden · Dresden, Germany
  • Helios Klinikum Erfurt · Erfurt, Germany
  • SRH Wald-Klinikum Gera GmbH · Gera, Germany
  • Ospedale Casa Sollievo Della Sofferenza · San Giovanni Rotondo, Italy
  • Azienda Ospedaliera Universitaria SS Antonio e Biagio e Cesare Arrigo · Alessandria, Italy
  • Ospedale San Vincenzo Taormina · Messina, Italy
  • Fondazione IRCSS - Istituto Nazionale dei Tumori · Milan, Italy
  • AOU Policlinico di Modena · Modena, Italy
  • Istituto Oncologico Veneto IRCCS · Padova, Italy
  • Azienda Provinciale per I Servizi Sanitari · Trento, Italy
  • IRCCS Ospedale Policlinico San Marino · Genoa, Italy
  • Maria Sklodowska-Curie Na;onal Research Ins;tute of Oncology, Gliwice Branch · Gliwice, Poland
  • TASK Eden · George, South Africa
  • Kyungpook National University Chilgok Hospital · Daegu, South Korea
  • Seoul National University Hospital · Seoul, South Korea
  • Hospital Clínico de Santiago de Compostela · Santiago de Compostela, Spain
  • Hospital Universitario Marques de Valdecilla · Santander, Spain
  • Hospital Clinico Universitario Virgen de la Arrixaca · Murcia, Spain
  • Hospital Clinic Barcelona · Barcelona, Spain
  • University Hospital of Jerez · Cadiz, Spain
Show 6 removed
  • CHU Lille · Polonovski, France
  • Universitat Leipzig · Saxony, Germany
  • TASK Eden · George Central, South Africa
  • Kyungpook National University Chilgok Hospital · Buk-Gu, South Korea
  • Seoul National University Hospital · Jongno-gu, South Korea
  • University Hospital of Jerez · Jerez de La Frontera (Cádiz), Spain
Oct 6, 2026
Contact
Study contact changed: K•••@eikontx.com · •••6163→K•••@eikontx.com · •••6163; removed b•••@eikontx.com · •••4170. See the current contact
Oct 6, 2026
Site contacts
Changed at 3 sites. See the sites
Show 3 sites
  • Aarhus Universitetshospital · Aarhus, DenmarkContact removed l•••@rm.dk · •••2026Contact removed l•••@auh.rm.dk · •••7216Contact removed (no phone or email listed)Contact removed (no phone or email listed)
  • Aalborg University Hospital · Aalborg, DenmarkContact removed l•••@rn.dk · •••1290Contact removed c•••@rn.dk · •••9874Contact removed (no phone or email listed)
  • Institut Català d'Oncologia Girona (ICO Girona) · Girona, SpainContact person changed (no phone or email listed)
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    26 sites added, 6 sites removed. 2 sites changed recruiting status (2 now suspended)
    Show 2 sites
    • Aarhus Universitetshospital · Aarhus, DenmarkRecruiting→Suspended
    • Aalborg University Hospital · Aalborg, DenmarkRecruiting→Suspended
    Show 26 added (8 Italy, 5 Germany, 5 Spain, 3 United States, 2 South Korea, 1 France, 1 Poland, 1 South Africa)
    • Christiana Care · Newark, United States
    • Florida Clinical Trials Group - Tamarac · Tamarac, United States
    • Patientcare Clinical Research · Sugar Land, United States
    • CHU Lille · Lille, France
    • University Hospital Erlangen · Erlangen, Germany
    • Universität Leipzig · Haus, Germany
    • University Hospital Carl Gustav Carus Dresden · Dresden, Germany
    • Helios Klinikum Erfurt · Erfurt, Germany
    • SRH Wald-Klinikum Gera GmbH · Gera, Germany
    • Ospedale Casa Sollievo Della Sofferenza · San Giovanni Rotondo, Italy
    • Azienda Ospedaliera Universitaria SS Antonio e Biagio e Cesare Arrigo · Alessandria, Italy
    • Ospedale San Vincenzo Taormina · Messina, Italy
    • Fondazione IRCSS - Istituto Nazionale dei Tumori · Milan, Italy
    • AOU Policlinico di Modena · Modena, Italy
    • Istituto Oncologico Veneto IRCCS · Padova, Italy
    • Azienda Provinciale per I Servizi Sanitari · Trento, Italy
    • IRCCS Ospedale Policlinico San Marino · Genoa, Italy
    • Maria Sklodowska-Curie Na;onal Research Ins;tute of Oncology, Gliwice Branch · Gliwice, Poland
    • TASK Eden · George, South Africa
    • Kyungpook National University Chilgok Hospital · Daegu, South Korea
    • Seoul National University Hospital · Seoul, South Korea
    • Hospital Clínico de Santiago de Compostela · Santiago de Compostela, Spain
    • Hospital Universitario Marques de Valdecilla · Santander, Spain
    • Hospital Clinico Universitario Virgen de la Arrixaca · Murcia, Spain
    • Hospital Clinic Barcelona · Barcelona, Spain
    • University Hospital of Jerez · Cadiz, Spain
    Show 6 removed
    • CHU Lille · Polonovski, France
    • Universitat Leipzig · Saxony, Germany
    • TASK Eden · George Central, South Africa
    • Kyungpook National University Chilgok Hospital · Buk-Gu, South Korea
    • Seoul National University Hospital · Jongno-gu, South Korea
    • University Hospital of Jerez · Jerez de La Frontera (Cádiz), Spain
    Contact Study contact changed: K•••@eikontx.com · •••6163→K•••@eikontx.com · •••6163; removed b•••@eikontx.com · •••4170. See the current contact
    Site contacts Changed at 3 sites. See the sites
    Show 3 sites
    • Aarhus Universitetshospital · Aarhus, DenmarkContact removed l•••@rm.dk · •••2026Contact removed l•••@auh.rm.dk · •••7216Contact removed (no phone or email listed)Contact removed (no phone or email listed)
    • Aalborg University Hospital · Aalborg, DenmarkContact removed l•••@rn.dk · •••1290Contact removed c•••@rn.dk · •••9874Contact removed (no phone or email listed)
    • Institut Català d'Oncologia Girona (ICO Girona) · Girona, SpainContact person changed (no phone or email listed)

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06697301
Lead sponsor
Eikon Therapeutics
Responsible party
Sponsor
First posted
Nov 20, 2024
Start date
May 22, 2025
Primary completion
Dec 2035 (estimated)
Completion
Dec 2040 (estimated)
Last update
Oct 6, 2026

Study contacts

Krishna Kaza, Director Clinical Study Management
Contact
Kazak@eikontx.com
+1 (516) 675-6163
Etah Kurland
study director · Eikon Therapeutics
Muaz Sadeia
study director · Eikon Therapeutics

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BDB001

Start the discussion